# Exothermic dark-photon dark matter and the LZ high-recoil event: finite-reheating constraints

Preprint · Kuldeep Deka

- Archive id: arxiv:2610.18974
- Published: 2026-10-13
- arXiv: https://arxiv.org/abs/2610.18974
- Source URL: https://arxiv.org/abs/2610.18974
- PDF: https://arxiv.org/pdf/2610.18974
- Provenance: arxiv

## Abstract

An excited dark-matter state can produce a high-energy nuclear recoil by releasing its mass splitting in a collision. Motivated by the $248$~keV LUX--ZEPLIN candidate, we study freeze-in of a $45$~GeV pseudo-Dirac particle with a $1$~MeV splitting and a $1$~GeV dark photon during non-instantaneous reheating. We choose a recoil normalization compatible with the published INTEGRAL/SPI three-photon decay limit. It predicts $0.43$ events in the LZ window and retains the reference recoil shape. Including both dark-photon and $Z$ exchange, we calculate production and entropy dilution for backgrounds with $T\\propto a^{-α}$ and $ρ\_φ\\propto a^{-3(1+ω)}$. For $\\Tmax=m\_χ$, the observed abundance requires $\\Trh=1.32$~GeV for matter-like constant-width reheating, $3.09$~GeV for quartic oscillations with scalar decay, and $0.588$~GeV for quartic oscillations with constant width, compared with $4.10$~GeV for instantaneous reheating. These finite-reheating solutions are insensitive to increasing $\\Tmax$ above $m\_χ$. For $\\Tmax\\geq m\_χ$, adiabatic kination has no solution with $\\Trh\>5.96$~MeV, the BBN-motivated cutoff adopted for our scans. At $α\_D=10^{-10}$, the estimated thermal-mediator source is below $0.2\\%$ of the Standard Model source, and self-conversion does not appreciably deplete the excited population. The calculation relates an exothermic recoil benchmark to the production and dilution history before radiation domination.

_Abstract reproduced under CC0-1.0 (arXiv descriptive metadata)._

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.